VCM
DYN icon

Voleon Capital Management’s Dyne Therapeutics DYN Stock Holding History

Voleon Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-111,838
Closed -$1.41M – 850
2025
Q3 		$1.41M Buy
111,838
+67,115
+150% +$765K 0.03% 360
2025
Q2 		$426K Sell
44,723
-14,950
-25% -$165K 0.02% 348
2025
Q1 		$624K Buy
+59,673
New +$854K 0.05% 244

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Voleon Capital Management's DYN Position: Q4 2025 in Review

Voleon Capital Management sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 111,838 shares — an estimated $1.41M sold.

Voleon Capital Management first reported a position in DYN in Q1 2025 and held it in 3 quarters. The position peaked at $1.41M in Q3 2025. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Voleon Capital Management reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Voleon Capital Management sold 111,838 Dyne Therapeutics shares in Q4 2025, an estimated $1.41M.
  • Voleon Capital Management first reported a position in Dyne Therapeutics in Q1 2025 and held it in 3 quarters.
  • Voleon Capital Management's Dyne Therapeutics position peaked at $1.41M in Q3 2025.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Voleon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.